Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christine Nikolic

Nurse Practitioner, Adult Health Mesa, AZ Nurse Practitioner

NPI 1760482574 CMS profile 11000659

6309 E Baywood Ave Ste 101, Mesa, AZ 85206

Open in the dashboard

General payments

$3,944

141 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christine Nikolic of Mesa, AZ is reported in the CMS Open Payments database as having received $3,944 across 141 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,046 37
2024 General $894 32
2023 General $596 25
2022 General $1,067 32
2021 General $341 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christine Nikolic
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Christine Nikolic were reported at $1,046. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Christine Nikolic Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $341 $138 $43–$438 $132
2022 $1,067 $165 $54–$494 $149
2023 $596 $178 $61–$549 $160
2024 $894 $186 $62–$575 $164
2025 $1,046 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $646 34 payments
  2. Merck Sharp & Dohme Corporation $528 23 payments
  3. Impulse Dynamics (USA) Inc. $423 4 payments
  4. Kestra Medical Technology Services, Inc. $319 15 payments
  5. Boston Scientific Corporation $269 3 payments
  6. Abbott Laboratories $266 7 payments
  7. Medtronic, Inc. $229 2 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $185 9 payments
  9. Sanofi-Aventis U.S. LLC $177 4 payments
  10. Esperion Therapeutics, Inc. $173 4 payments
  11. Other $729 36 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,733 136 payments
  2. Education $173 4 payments
  3. Long term medical supply or device loan $39 1 payment
Products named General payments · program years 2021–2025
  1. VERQUVO $586 26 payments
  2. LEQVIO $579 29 payments
  3. ENTRESTO $317 15 payments
  4. Optimizer Cardiovascular $257 3 payments
  5. Optimizer Cardiovascular $248 2 payments
  6. WATCHMAN FLX $246 2 payments
  7. CARDIOMEMS $215 4 payments
  8. Assure WCD $205 10 payments
  9. NEXLETOL $173 4 payments
  10. OPTIMIZER Cardiovascular Device $166 1 payment
  11. Other $1,866 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

4,482

Median for Nurse Practitioner: 389

Drug cost

$1,320,085

Median for Nurse Practitioner: $21,885

Branded share of claims

35.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 590 $554,684
Jardiance Empagliflozin Brand 282 $249,864
Eliquis Apixaban Brand 186 $226,162
Farxiga Dapagliflozin Propanediol Brand 215 $156,681
Xarelto Rivaroxaban Brand 59 $63,605
Brilinta Ticagrelor Brand 39 $23,081
Metoprolol Succinate Generic 353 $4,736
Eplerenone Generic 34 $3,150
Spironolactone Generic 471 $2,906
Potassium Chloride Generic 147 $2,857

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $226
$226 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $132
$132 590 —
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $103
$103 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $65
$65 282 —
VERQUVO
  • Merck Sharp & Dohme Corporation $58
$58 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

141 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record